Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook
FOLD reports preliminary fourth-quarter and full-year 2024 total revenues. The company also outlines key strategic goals for 2025.
Amicus Therapeutics: Cheap Heading Into 2025
Amicus Therapeutics, Inc.'s shares are down 15% recently despite a profitable 3Q24 and raised FY24 outlook, potentially due to market overreaction. The company markets Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease. Galafold dominates its market segment, and a licensing deal with Teva de-risks future growth, positioning it for a continued revenue increase.
Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
FOLD's third-quarter 2024 earnings and sales beat the Zacks Consensus Estimate. The company raises its financial guidance for 2024.
Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings
The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Simon Harford - CFO Ellen Rosenberg - Chief Legal Officer Conference Call Participants Ritu Baral - TD Cowen Anupam Rama - JP Morgan Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Joe Schwartz - Leerink Partners Dae Gon Ha - Stifel Dennis Ding - Jefferies Kristen Kluska - Cantor Fitzgerald Michael Riad - Morgan Stanley Gil Blum - Needham & Company Salveen Richter - Goldman Sachs Operator Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Third Quarter 2024 Financial Results Conference Call and Webcast.
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.07 per share a year ago.
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know
The consensus price target hints at a 51.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
